AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Features linked to antibody protection against ricin determined.
2004 AUG 4 - (NewsRx.com & NewsRx.net) -- Scientists have determined the immunological characteristics associated with the protective efficacy of antibodies to ricin.
According to published research from the United States, "A/B toxins, produced by bacteria and plants, are among the deadliest molecules known. The B chain binds the cell, whereas the A chain exerts the toxic effect. Both anti-A chain and anti-B chain antibodies can neutralize toxins in vivo and in vitro. B chain antibodies block binding of the toxin to the cell. It is not known how anti-A chain antibodies function."
"Working with ricin toxin, we demonstrate that immunization with A chain induces greater protection than immunization with B chain," stated Massimo Maddaloni and collaborators at Montana State University and Louisiana State University. "A panel of mAbs, binding to A chain, B chain, or both chains, has been produced and characterized. Immunologic characteristics evaluated include isotype, relative avidity, and epitope specificity. The ability to inhibit ricin enzymatic or cell binding activity was studied, as was the ability to block ricin-mediated cellular cytotoxicity on human and murine cell lines. Finally, the in vivo protective efficacy of the antibodies in mice was studied."
"The antibody providing the greatest in vivo protective efficacy was directed ...
- Inhibition of membrane-type serine protease 1 by human single-chain antibodies.
- Newspaper article from: Immunotherapy Weekly April 2, 2003 700+ words
...of membrane-type serine protease 1 by human single-chain antibodies. According to a study from the United States, "Specific...of membrane-type serine protease 1 by human single-chain antibodies. Biochemistry, 2003;42(4):892-900). The corresponding...
- Micromet and EvoGenix Pty Ltd sign licence agreement for single-chain...
- News wire article from: Asia Africa Intelligence Wire December 23, 2004 700+ words
...Pharmaceuticals Inc's combined patent estates in the field of single-chain antibodies. Under the terms of the agreement, EvoGenix will apply single-chain antibodies technology in combination with its proprietary EvoGene technology for...
- Micromet AG, of Munich, Germany, licensed some of the patents in single-chain...
- Newspaper article from: BioWorld International January 5, 2005 700+ words
...Munich, Germany, licensed some of the patents in single-chain antibodies it holds jointly with Enzon Pharmaceuticals Inc. to EvoGenix...of Sydney, Australia. EvoGenix will use single-chain antibodies together with its proprietary technology to create and...
- Micromet AG, of Munich, Germany, reached an agreement with Merck & Co. Inc., of...
- Newspaper article from: BioWorld International July 21, 2004 700+ words
...granting Merck a research license for the patents in single-chain antibodies that are jointly held by Micromet and Enzon Pharmaceuticals...Enzon. It is the fifth license agreement covering single-chain antibodies closed by the partnership of Micromet and Enzon.
- Micromet AG, of Munich, Germany, licensed its patent portfolio in single-chain...
- Newspaper article from: BioWorld International April 28, 2004 700+ words
* Micromet AG, of Munich, Germany, licensed its patent portfolio in single-chain antibodies (SCA) on a global, but nonexclusive basis, to BioInvent International AB, of Stockholm, Sweden. BioInvent will receive a...
- Micromet, Enzon collaborate on single-chain antibodies.(Brief Article)
- Newspaper article from: BioWorld International Merrill, Douglas April 17, 2002 700+ words
MUNICH, Germany -- Micromet AG and Enzon Inc. entered a collaboration to identify and develop treatments based on antibody fragments. The companies will combine their patent estates, cooperate on single-chain antibody (SCA) technology and establish a new R&D unit located at Micromet's research
- Micromet and ESBATech enter patent licence agreement on single-chain antibodies.
- News wire article from: Asia Africa Intelligence Wire May 13, 2003 700+ words
(From Chemical Business NewsBase - Press Release) Micromet AG and ESBATech AG entered into an intellectual property licence agreement, under which ESBATech receives a world-wide, non-exclusive licence to Micromet's and Enzon's combined single-chain antibody (SCA) patents for use in ESBATech's
- Micromet, Enzon and Cambridge Antibody Technology Sign Cross-Licence Agreement...
- Press release article from: Business Wire September 3, 2003 700+ words
Business Editors/Health/Medical Writers BRIDGEWATER, N.JBUSINESS WIRESept. 3, 2003 Cambridge Antibody Technology (LSE:CAT; NASDAQ:CATG), Micromet AG, and Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) Expanded Opportunities for the Development of Novel Antibody Therapeutic Products Cambridge Antibody
- Florida State University Standardizes on Business Objects.
- Press release article from: Business Wire December 1, 2004 700+ words
...today announced that Florida State University has standardized on a BI solution...Business Objects. Florida State University uses Business Objects to track...Business Objects, Florida State University is pioneering the use of BI...
- Iowa State University Becomes 22nd Clinical Training Affiliate of Ross...
- Press release article from: Business Wire January 4, 2005 700+ words
...medical education, announced that Iowa State University College of Veterinary Medicine will...As an affiliated institution, Iowa State University will provide Ross University students...the same academic standards as Iowa State University standards. After completing the clinical...
Source: HighBeam Research, Features linked to antibody protection against ricin determined.